Drug Profile
Terbinafine iontophoretic - NB Therapeutics
Alternative Names: NBT-320Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Transport Pharmaceuticals
- Developer NB Therapeutics
- Class Amines; Antifungals; Naphthalenes; Skin disorder therapies; Small molecules
- Mechanism of Action Squalene monooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Onychomycosis
Most Recent Events
- 30 Jun 2012 NB Therapeutics completes a phase II trial in Onychomycosis in USA & Canada (NCT01080079)
- 30 Apr 2012 NB Therapeutics completes a phase II trial in Onychomycosis in USA (NCT01484145)
- 22 Dec 2011 NB Therapeutics initiates enrolment in a phase II trial for Onychomycosis in USA (NCT01484145)